Ivabradine Macleods Pharma Uk

Active Ingredient:: Ivabradine Oxalate
Origin:: EU

Ivabradine Macleods Pharma Uk (Ivabradine Oxalate)

Q: What conditions is Ivabradine used for?

Ivabradine is prescribed for chronic stable angina pectoris and for heart failure with reduced ejection fraction (NYHA class II–III). In both cases it works by lowering the heart rate, which reduces myocardial oxygen demand and improves exercise tolerance.

Q: How does Ivabradine work in the body?

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the pacemaker of the heart. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, leading to a reduction in resting heart rate without affecting contractility or blood pressure.

Q: What is the usual dose of Ivabradine?

The dosage of Ivabradine is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerability. The prescriber will set the appropriate strength and dosing schedule according to approved labeling.

Q: Is Ivabradine safe to use during pregnancy or breastfeeding?

Safety data for Ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Q: How do I order Ivabradine Macleods Pharma Uk from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Ivabradine compare with beta‑blockers?

Both Ivabradine and beta‑blockers lower heart rate, but Ivabradine does so without affecting myocardial contractility or blood pressure, making it useful for patients who cannot tolerate beta‑blockers or need additional heart‑rate control beyond what beta‑blockers provide.

Q: What are the recommended storage conditions for Ivabradine?

Store Ivabradine tablets at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Q: How is Ivabradine administered?

Ivabradine is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. It is typically taken with or without food as directed by the prescribing physician.

Q: What are the most serious risks associated with Ivabradine?

Serious risks include symptomatic bradycardia, atrial fibrillation, advanced atrioventricular block, worsening heart failure, and severe visual disturbances such as persistent photopsia. Patients should be monitored closely for these events, especially during treatment initiation.

Q: Who should not use Ivabradine?

Ivabradine is contraindicated in patients with severe bradycardia (resting heart rate <50 bpm), sick sinus syndrome, second‑ or third‑degree AV block without a pacemaker, and in those taking strong CYP3A4 inhibitors that cannot be discontinued.

Ivabradine, the active ingredient in Ivabradine Macleods Pharma Uk, is an If channel inhibitor presented as a oral tablet for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate adult patients.

GNH India supplies Ivabradine Macleods Pharma Uk as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Macleods Pharma Uk Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine is used to manage conditions related to cardiac ischemia and heart failure by selectively lowering heart rate.

Chronic stable angina pectoris: reduces frequency of angina attacks by decreasing myocardial oxygen demand.
Heart failure with reduced ejection fraction (NYHA class II–III): improves exercise capacity and may reduce hospitalisation by lowering heart rate.
Exercise intolerance in heart failure: enhances functional capacity through heart‑rate reduction.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which slows spontaneous depolarisation. This reduces resting heart rate without affecting myocardial contractility or systemic blood pressure, thereby decreasing cardiac oxygen consumption.

Side Effects

Adverse reactions may occur with ivabradine therapy.

Common Side Effects

Visual disturbances (phosphenes): transient luminous phenomena.
Bradycardia: resting heart rate below 50 bpm.
Headache.
Dizziness.
Fatigue.
Blurred vision.

Serious or Rare Side Effects

Symptomatic severe bradycardia requiring medical intervention.
Atrial fibrillation or other arrhythmias.
Heart block (advanced AV block).
Worsening heart failure.
Severe visual disturbances (persistent photopsia).
Hypotension leading to syncope.

Precautions & Warnings

Ivabradine requires careful patient assessment and monitoring.

Dose adjustment: reduce dose in patients with moderate hepatic impairment.
Avoid use in severe bradycardia (resting HR <50 bpm) or sick sinus syndrome.
Monitor heart rate regularly to maintain target range.
Caution with concomitant CYP3A4 inhibitors, which may increase plasma levels.
Pregnancy: safety not established; use only if potential benefit justifies the risk.
Store at ambient temperature: keep in the original pack, protect from moisture and light.

Avoid Interactions

Ivabradine may interact with several medicines.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine concentrations.
Concomitant bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction.
Verapamil or diltiazem (CYP3A4 inhibitors): can increase ivabradine exposure.

Moderate Interactions (Monitor Closely)

CYP3A4 inducers (e.g., rifampicin): may lower ivabradine effectiveness.
Other antiarrhythmics (e.g., amiodarone): require heart‑rate monitoring.
Antihypertensives: may have additive effects on heart rate and require dose adjustments.

Frequently Asked Questions

Ivabradine is prescribed for chronic stable angina pectoris and for heart failure with reduced ejection fraction (NYHA class II–III). In both cases it works by lowering the heart rate, which reduces myocardial oxygen demand and improves exercise tolerance.

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the pacemaker of the heart. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, leading to a reduction in resting heart rate without affecting contractility or blood pressure.

The dosage of Ivabradine is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerability. The prescriber will set the appropriate strength and dosing schedule according to approved labeling.

Safety data for Ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Ivabradine and beta‑blockers lower heart rate, but Ivabradine does so without affecting myocardial contractility or blood pressure, making it useful for patients who cannot tolerate beta‑blockers or need additional heart‑rate control beyond what beta‑blockers provide.

Store Ivabradine tablets at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Ivabradine is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. It is typically taken with or without food as directed by the prescribing physician.

Serious risks include symptomatic bradycardia, atrial fibrillation, advanced atrioventricular block, worsening heart failure, and severe visual disturbances such as persistent photopsia. Patients should be monitored closely for these events, especially during treatment initiation.

Ivabradine is contraindicated in patients with severe bradycardia (resting heart rate <50 bpm), sick sinus syndrome, second‑ or third‑degree AV block without a pacemaker, and in those taking strong CYP3A4 inhibitors that cannot be discontinued.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.